FREE/TOTAL PROSTATE SPECIFIC ANTIGEN RATIO AS PREDICTOR FOR PROSTATE CARCINOMA

Sajjad Ahmad, Abdul Ghafar, Ghazi Khan

Abstract


Background: Prostate-specific antigen (PSA) is a tumor marker helpful in the diagnosis and follow-up of prostate cancer. Objective of the study was to determine Free/total PSA ratio as a predictor of prostate carcinoma.
Material and Methods: This cross-sectional study was carried in the Department of Histopathology, Shaikh Zayed Hospital, Lahore during December, 2006 to July, 2007. Hundred patients were asked to consent for blood sample for PSA analysis. The prostate tissue was preserved in fixative solution (10% buffered) neutral formalin. Multiple sections were stained with Haematoxylin and Eosin and examined microscopically. The demographic variable was age. The research variables were fPSA/tPSA ratio, morphology of prostate, tPSA and fPSA. Frequency and percentage were calculated for categorical whereas mean and standard deviation (SD) for numeric variables. The findings were recorded in proforma. Histopathology was taken as gold standard. The data was entered in SPSS version 10 and analyzed accordingly.
Results: Mean TPSA was found to be higher in carcinoma cases (25.7±21.6 ng/mL) and was lower in the benign cases (12.7±6.9 ng/mL). Moreover, a majority of the carcinoma cases had serum PSA >10 ng/mL. Using a free-PSA “cut-off” of 25% to differentiate between benign and malignant prostate enlargement.
Conclusion: This study concludes that there is highly significant increase in tPSA level in cases of prostate carcinoma whereas fPSA/tPSA ratio significantly increases in BPH cases as compared to prostate carcinoma. Therefore fPSA/tPSA ratio can be a useful predictor for early detection of prostate carcinoma.

Keywords


Free prostate- specific antigen; Prostate; carcinoma.

Full Text:

PDF

References


Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11–30.

Pu YS, Chiang HS, Lin CC, Huang CY, Huang KH, Chen J. Changing trends of prostate cancer in Asia. Aging Male 2004; 7: 120-32.

Elgamal AA, Holmes EH, Su LS, Tino WT, Sinmons SJ, Peterson M, et al. Prostate specific membrane antrogen current benefits and future value. Semin Surg Oncol 2000; 18: 10-6.

Ghafoor F, Khan S, Suleman B, Khan A. Evaluation of prostate specific antigen as a tumor marker in cancer prostate. JPMA 1998; 48: 360-3.

Bryden AA, Freemont AJ, Clarke NW, George NJR. Ki-67 index in metastatic prostate cancer. Eur Urol 2001; 40: 673-6.

Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 2002; 325: 740-3.

Ahmed S. Elisa and electrophoretic analysis of serum proteins in benign prostatic hyperplasia [Thesis]. Lahore: University of the Punjab, 2000; 6-8.

Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 2003; 21: 383-7.

Becker C, Piironen T, Pettersson K. Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater. Urol 2000;55:694-9.

Battikhi MN, Hussein I. Age-specific reference ranges for prostate specific antigen-total and free in patients with prostatitis symptoms and patients at risk. Int Urol Nephrol 2006; 38: 559-64.

Lojanapiwat B, Anutrakulchai W, Chongruksut W, Chongruksut W, Udomphot C. Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice. Prostate Int 2014;2:133-9.

Naz S, Sara A, Farkhanda G, Butt NS, Akhtar W. Free and total prostate specific antigen in benign prostatic hyperplasia and prostate cancer. J Coll Physcians Surg Pak 2004; 14: 69-71.

Yilmaz H, Ciftci S, Yavuz U, Ustuner M, Saribacak A, Dillioglugil O. Percentage of free prostate-specific antigen (PSA) is a useful method in deciding to perform prostate biopsy with higher core numbers in patients with low PSA cut-off values. KJMS 2015; 31:315-9.

Bjartell A, Johansson R, Bjork T, Gadaleanu V, Lundwall A, Lilja H, et al. Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland. Prostate 2006; 66: 591-603.

Junker R, Brandt B, Zecdhel C, Assmann G. Comparison of PSA measured by four combinations of free-PSA and total PSA assays. Clin Chem 1997; 43: 1588-94.

Iqbal N, Bhatti AN, Hussain S. Role of digital rectal examination and prostate specific antigen in detecting carcinoma prostate. J Coll Physicians Surg Pak 2003; 13: 340-2.

Lee R, Localio AR, Armstrong K, Malkowicz SB, Schwartz JS. A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urol 2006; 67:762-8.

Malati T, Kumari GR, Murthy PV, Reddy CR, Prakash BS. Prostate specific antigen in patients of benign prostate hypertrophy and carcinoma prostate. Indian J Clin Biochem 2006; 21:34-40.

Aleem, Ahmad M, Zamir M, Tasneem RA, Sultana K.Comparison of free / total prostate specific antigen (PSA) in benign prostatic hyperplasia and carcinoma prostate. J Allama Iqbal Med Coll 2008; 5:31-45.


Refbacks

  • There are currently no refbacks.


© 2011 Gomal Journal of Medical Sciences